Clinical Trial Update: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

View source ↗

Summary

Reports the completion of a safety follow-up study of brexpiprazole (Rexulti) versus placebo in subjects with agitation associated with Alzheimer's disease who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• REXULTI (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Agitation Associated With Alzheimer's Disease, Alzheimer's Type | Status: COMPLETED